Kalohexis Files Confidential IPO to Expand Obesity Portfolio
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowKalohexis has filed confidentially for an initial public offering (IPO) with the US Securities and Exchange Commission (SEC) to support its therapies targeting obesity and cancer cachexia. The company, which spun out from Endevica Bio in March 2026, has two clinical-stage programs: mifomelatide and 710GO. Currently, the estimated sales in the obesity market could reach $173.5 billion by 2031 across major markets. This move reflects the growing trend of biotech companies going public in 2026, which could present new investment opportunities for ordinary investors.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
